skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

ジェネリック医薬品、バイオシミラーの情報源として

Generics_Bulletin2

日本国内では2020年9月までにジェネリック医薬品の使用割合を80%にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト&ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析&報告します。

Generics Bulletinでは以下のトピックをカバーしています。

  • 規制・コンプライアンスの変更
  • 法規制の進展
  • 競合製品の開発
  • 合併・買収活動
  • 新製品の発売
  • マーケティングの課題
  • 広告戦略など

このサービスの特徴

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    California Plans To Create Own Generics Label

    15 Jan 2020

    California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biocon Biologics Gets True North Investment

    By Vibha Ravi 08 Jan 2020

    Biocon_Biologics_Gets_True_North_Investment

    Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

    Topic deal-trends strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Alberta Is Second Canadian Province To Switch To Biosimilars

    18 Dec 2019

    Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Global Industry Hails Bioequivalence Progress

    By Aidan Fry 11 Dec 2019

    For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Ophthalmics Are Next Frontier For Teligent

    06 Dec 2019

    US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion's Remsima SC Ready For Early 2020 Launch

    28 Nov 2019

    Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Amneal Starts Seeking International Partners

    20 Nov 2019

    In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

    Topic Business strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Accord Strikes Thiotepa Deal With Adienne

    By Aidan Fry 20 Nov 2019

    Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.

    Topic business-strategies cancer

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Aurobindo Is Company Of The Year At GGB Awards

    13 Nov 2019

    Article

    Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.

    Topic biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Lupin Offloads Kyowa For $525m But Not Exiting Japan

    By Vibha Ravi 13 Nov 2019

    Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

    Topic deal-trends strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva Debuts US Rituximab At A 10% Discount

    08 Nov 2019

    Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

    Topic biosimilars strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    The US Biosimilars Perspectives

    04 Nov 2019

    The US Biosimilars Perspectives

    As the push to promote the uptake of biosimilars in the US gains more momentum, new opportunities and challenges arise. Keep in tune with important developments in this impactful area using market coverage from Generics Bulletin. 

    Topic biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Pfizer Lines Up Trio Of US Biosimilar Launches

    01 Nov 2019

    Pfizer_Lines_Up_1

    By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.

    Topic business-strategies drug-development-landscape

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, Pink Sheet: 世界の薬事規制と承認審査に関するニ...

    Mega Mergers

    30 Sep 2019

    Mega Mergers

    When it comes to M&A, Informa Pharma Insights has got it covered. Our readers benefit from exclusive executive interviews with industry leaders and expert analysts on business, pipeline and M&A strategy, broad and detailed coverage on implications of deal-making from antitrust to quality compliance, commercial and R&D infrastructure, regional repercussions and the impact on existing partners. 2019 has already been notable for major deals, from the closing of the $62bn Takeda/Shire acquisition to the agreed purchases of Celgene for $74bn by Bristol-Myers Squibb and of Allergan for $63bn by AbbVie, to Pfizer’s plan to merge its Upjohn generics business with Mylan.

    Topic business-strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Corporate Strategies of the biggest Generics and Biosimilar players

    17 Sep 2019

    Corporate Strategies of the biggest Generics and Biosimilar players

    Understand the latest Corporate Strategies of the biggest Generics and Biosimilar players.

    Topic business-strategies

医薬品産業専門のジャーナリスト&アナリスト

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。